Cargando…

Efficacy and safety of Gemogenovatucel-T (Vigil) immunotherapy for advanced ovarian carcinoma: A systematic review and meta-analysis of randomized controlled trials

In recent years, many clinical trials have shown the safety and efficacy of Gemogenovatucel-T (Vigil) in the treatment of advanced OC patients. The purpose of this study was to explore the safety and efficacy of Gemogenovatucel-T (Vigil) in the first-line maintenance of advanced ovarian carcinoma ba...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Yixin, Zhang, Li, Zhao, Yuli, Wang, Sen, Feng, Li
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9634109/ https://www.ncbi.nlm.nih.gov/pubmed/36338747 http://dx.doi.org/10.3389/fonc.2022.945867

Ejemplares similares

Long-Term Follow-Up of Gemogenovatucel-T (Vigil) Survival and Molecular Signals of Immune Response in Recurrent Ovarian Cancer
por: Rocconi, Rodney P., et al.
Publicado: (2021)

Pilot Study of Combination Gemogenovatucel-T (Vigil) and Durvalumab in Women With Relapsed BRCA-wt Triple-Negative Breast or Ovarian Cancer
por: Barve, Minal, et al.
Publicado: (2022)

Efficacy and safety of neoadjuvant immunotherapy combined with chemotherapy in locally advanced esophageal cancer: A meta-analysis
por: Wang, Jincheng, et al.
Publicado: (2022)

Evaluation of the Efficacy and Safety of PARP Inhibitors in Advanced-Stage Epithelial Ovarian Cancer
por: Jiang, Yifan, et al.
Publicado: (2020)

ENTPD1/CD39 as a predictive marker of treatment response to gemogenovatucel-T as maintenance therapy in newly diagnosed ovarian cancer
por: Rocconi, Rodney P., et al.
Publicado: (2022)

Efficacy and Safety of Cellular Immunotherapy by Local Infusion for Liver Tumor: A Systematic Review and Meta-Analysis
por: Chen, Shanshan, et al.
Publicado: (2022)

Efficacy and Safety of Placebo During the Maintenance Therapy of Ovarian Cancer in Randomized Controlled Trials: A Systematic Review and Meta-analysis
por: Wang, Jin-feng, et al.
Publicado: (2022)

Real-World Efficacy and Safety of Anlotinib With and Without Immunotherapy in Advanced Non-Small Cell Lung Cancer
por: Xiong, Qi, et al.
Publicado: (2021)

Comparison of Efficacy and Safety Between Immunotherapy and Docetaxel Monotherapy in NSCLC Patients
por: Yang, Wenchao, et al.
Publicado: (2022)

Author Correction: ENTPD1/CD39 as a predictive marker of treatment response to gemogenovatucel-T as maintenance therapy in newly diagnosed ovarian cancer
por: Rocconi, Rodney P., et al.
Publicado: (2023)

Gynecologists Need to Be Vigilant—Two Case Reports of Intravascular Leiomyomatosis and Literature Review
por: Li, Xiang, et al.
Publicado: (2022)

Comparative Efficacy and Safety of Immunotherapy Alone and in Combination With Chemotherapy for Advanced Non-small Cell Lung Cancer
por: Wang, Xue, et al.
Publicado: (2021)

The efficacy and safety of different systemic combination therapies on advanced hepatocellular carcinoma: a systematic review and meta-analysis
por: Li, Ping, et al.
Publicado: (2023)

Efficacy and safety of lenvatinib versus sorafenib in first-line treatment of advanced hepatocellular carcinoma: A meta-analysis
por: Luo, Jia, et al.
Publicado: (2022)

Efficacy and Safety of PARP Inhibitor Combination Therapy in Recurrent Ovarian Cancer: A Systematic Review and Meta-Analysis
por: Ren, Ning, et al.
Publicado: (2021)

Advanced development of biomarkers for immunotherapy in hepatocellular carcinoma
por: Peng, Xuenan, et al.
Publicado: (2023)

Molecular targeted therapy and immunotherapy in advanced hepatocellular carcinoma: a systematic review and Bayesian network meta-analysis based on randomized controlled trials
por: Zhang, Yun-Long, et al.
Publicado: (2023)

Efficacy and Safety of Immune Checkpoint Inhibitor in Advanced Esophageal Squamous Cell Carcinoma: A Meta-Analysis
por: Gu, Yi-Min, et al.
Publicado: (2021)

Efficacy and Safety of Chinese Herbal Medicine on Ovarian Cancer After Reduction Surgery and Adjuvant Chemotherapy: A Systematic Review and Meta-Analysis
por: Wang, Rongyun, et al.
Publicado: (2019)

PARP Inhibitors in Patients With Newly Diagnosed Advanced Ovarian Cancer: A Meta-Analysis of Randomized Clinical Trials
por: Wang, Yizi, et al.
Publicado: (2020)

Comparison of the Efficacy and Safety of PARP Inhibitors as a Monotherapy for Platinum-Sensitive Recurrent Ovarian Cancer: A Network Meta-Analysis
por: Wang, Hongmei, et al.
Publicado: (2021)

Comparison of Efficacy and Safety of Third-Line Treatments for Advanced Gastric Cancer: A Systematic Review With Bayesian Network Meta-Analysis
por: Huang, Miao, et al.
Publicado: (2021)

Efficacy and Safety of First-Line Chemotherapies for Patients With Advanced Biliary Tract Carcinoma: A Systematic Review and Network Meta-Analysis
por: Jiang, Yanfeng, et al.
Publicado: (2021)

Efficacy and Safety of Minimally Invasive Surgery Versus Open Laparotomy for Interval Debulking Surgery of Advanced Ovarian Cancer After Neoadjuvant Chemotherapy: A Systematic Review and A Meta-Analysis
por: Zeng, Siyuan, et al.
Publicado: (2022)

Efficacy and safety of zolbetuximab for first-line treatment of advanced Claudin 18. 2-positive gastric or gastro-esophageal junction adenocarcinoma: a systematic review and meta-analysis of randomized controlled trials
por: Liang, Zhanpeng, et al.
Publicado: (2023)

The Efficacy and Safety of Hypofractionated Radiation Therapy With Tomotherapy for Advanced or Recurrent Hepatocellular Carcinoma
por: Shen, Jie, et al.
Publicado: (2021)

Safety and efficacy of the pan-FGFR inhibitor erdafitinib in advanced urothelial carcinoma and other solid tumors: A systematic review and meta-analysis
por: Zheng, Xinyi, et al.
Publicado: (2023)

Efficacy and safety of (177)Lu-DOTATATE targeted therapy in advanced/metastatic pulmonary neuroendocrine tumors: A systematic review and meta-analysis
por: Ma, Jiao, et al.
Publicado: (2022)

Efficacy of immunotherapy in KRAS-mutant advanced NSCLC: A real-world study in a Chinese population
por: Peng, Lixiu, et al.
Publicado: (2023)

Safety of PD-1/PD-L1 Inhibitors Combined With Palliative Radiotherapy and Anti-Angiogenic Therapy in Advanced Hepatocellular Carcinoma
por: Zhong, Liting, et al.
Publicado: (2021)

Advances in molecular and cell therapy for immunotherapy of cholangiocarcinoma
por: Zhao, Li-ming, et al.
Publicado: (2023)

Comparison of the efficacy and safety of third-line treatments for advanced gastric cancer: A systematic review and network meta-analysis
por: Zhang, Chan, et al.
Publicado: (2023)

Commentary: Efficacy and Safety of Chinese Herbal Medicine on Ovarian Cancer After Reduction Surgery and Adjuvant Chemotherapy: A Systematic Review and Meta-Analysis
por: Li, Mingxing, et al.
Publicado: (2020)

Efficacy and safety of taxanes combined with chemotherapy drugs in advanced triple negative breast cancer: A meta-analysis of 26 randomized controlled trials
por: Huang, Qionglian, et al.
Publicado: (2022)

Efficacy and safety of radiotherapy/chemoradiotherapy combined with immune checkpoint inhibitors for locally advanced stages of esophageal cancer: A systematic review and meta-analysis
por: Wu, Jing, et al.
Publicado: (2022)

Cancer Stemness Associated With Prognosis and the Efficacy of Immunotherapy in Adrenocortical Carcinoma
por: Shi, Xiaoxi, et al.
Publicado: (2021)

Efficacy and safety of acupuncture-point stimulation combined with opioids for the treatment of moderate to severe cancer pain: a network meta-analysis of randomized controlled trials
por: Zhang, Qinglin, et al.
Publicado: (2023)

Evaluation of tumour vaccine immunotherapy for the treatment of advanced non-small cell lung cancer: a systematic meta-analysis
por: Wang, Min, et al.
Publicado: (2015)

The short-term efficacy and safety of induction chemotherapy combined with PD-1 inhibitor or anti-EGFR in locoregionally advanced nasopharyngeal carcinoma
por: Xiang, Xiaoyong, et al.
Publicado: (2023)

Efficacy and safety of apatinib monotherapy for patients with advanced breast cancer: a systematic review and meta-analysis
por: Huang, Xuchen, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_jqtshm4i2oubiuikrs9mvrs7or